CL2019002540A1 - Fabricación de un producto farmacéutico cristalino. - Google Patents
Fabricación de un producto farmacéutico cristalino.Info
- Publication number
- CL2019002540A1 CL2019002540A1 CL2019002540A CL2019002540A CL2019002540A1 CL 2019002540 A1 CL2019002540 A1 CL 2019002540A1 CL 2019002540 A CL2019002540 A CL 2019002540A CL 2019002540 A CL2019002540 A CL 2019002540A CL 2019002540 A1 CL2019002540 A1 CL 2019002540A1
- Authority
- CL
- Chile
- Prior art keywords
- around
- manufacture
- pharmaceutical product
- crystalline pharmaceutical
- pirazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA INVENCIÓN ACTUAL SE REFIERE A PARTÍCULAS CRISTALINAS DE N-((S)-1-(3-(3-CLORO-4-CIANO¬FENIL)-1H-PIRAZOL-1-IL)-PROPAN-2-IL)-5-(1- HIDROXI¬ETIL)-1H-PIRAZOL-3-CARBOXAMIDA (I) QUE TIENEN UN ÁREA DE SUPERFICIE ESPECÍFICA (SSA) EN EL INTERVALO DESDE ALREDEDOR DE 8 HASTA ALREDEDOR DE 16 M2/G, PREFERIBLEMENTE DESDE ALREDEDOR DE 10 HASTA ALREDEDOR DE 15 M2/G, Y AL MÉTODO PARA LA PREPARACIÓN DE TALES PARTÍCULAS. EL COMPUESTO (I) ES UN MODULADOR DEL RECEPTOR DE ANDRÓGENO (AR) POTENTE QUE ES ÚTIL COMO UN MEDICAMENTO POR EJEMPLO EN EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20175202 | 2017-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002540A1 true CL2019002540A1 (es) | 2020-01-31 |
Family
ID=61599196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002540A CL2019002540A1 (es) | 2017-03-07 | 2019-09-04 | Fabricación de un producto farmacéutico cristalino. |
| CL2023002780A CL2023002780A1 (es) | 2017-03-07 | 2023-09-20 | Fabricación de un producto farmacéutico cristalino |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002780A CL2023002780A1 (es) | 2017-03-07 | 2023-09-20 | Fabricación de un producto farmacéutico cristalino |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11168058B2 (es) |
| EP (2) | EP3592732B1 (es) |
| JP (1) | JP7157071B2 (es) |
| KR (3) | KR20250065940A (es) |
| CN (2) | CN110382467B (es) |
| AU (1) | AU2018229817B2 (es) |
| BR (1) | BR112019018458A2 (es) |
| CA (1) | CA3055019A1 (es) |
| CL (2) | CL2019002540A1 (es) |
| DK (1) | DK3592732T3 (es) |
| EA (1) | EA201992103A1 (es) |
| ES (1) | ES3027971T3 (es) |
| FI (1) | FI3592732T3 (es) |
| HR (1) | HRP20250684T1 (es) |
| HU (1) | HUE071505T2 (es) |
| LT (1) | LT3592732T (es) |
| MX (1) | MX2019010452A (es) |
| NZ (1) | NZ797194A (es) |
| PL (1) | PL3592732T3 (es) |
| PT (1) | PT3592732T (es) |
| RS (1) | RS66855B1 (es) |
| SI (1) | SI3592732T1 (es) |
| UA (1) | UA126071C2 (es) |
| WO (1) | WO2018162793A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021515040A (ja) | 2018-02-27 | 2021-06-17 | サンド・アクチエンゲゼルシヤフト | ダロルタミドの結晶形態ｉｉ |
| WO2020157699A1 (en) | 2019-01-30 | 2020-08-06 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| JP7577698B2 (ja) * | 2019-07-02 | 2024-11-05 | オリオン コーポレーション | ダロルタミドの医薬組成物 |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| WO2022144926A1 (en) * | 2020-12-31 | 2022-07-07 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide |
| MX2024009980A (es) | 2022-02-28 | 2024-08-26 | Quim Sintetica S A | Forma cristalina de darolutamida. |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006307470A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Pharmaceutical formulation of losartan |
| WO2008146590A1 (ja) * | 2007-05-28 | 2008-12-04 | Mitsubishi Shoji Foodtech Co., Ltd. | 球形マンニトール結晶粒子 |
| US20100234469A1 (en) * | 2009-03-12 | 2010-09-16 | Medichem, S.A. | New Crystals Of A Benzoylbenzeneacetamide Derivative |
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| ES2541295T3 (es) | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
| AU2012250799A1 (en) * | 2011-05-04 | 2013-10-10 | Merck Sharp & Dohme Corp. | Processes for preparing inhibitors of the hepatitis C virus |
| DK3250554T3 (da) | 2015-01-30 | 2022-06-27 | Orion Corp | Carboxamidderivat og diastereomerer deraf i stabil, krystallinsk form |
| JP6716023B2 (ja) | 2016-08-26 | 2020-07-01 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
-
2018
- 2018-02-27 FI FIEP18709661.5T patent/FI3592732T3/fi active
- 2018-02-27 BR BR112019018458A patent/BR112019018458A2/pt not_active Application Discontinuation
- 2018-02-27 PT PT187096615T patent/PT3592732T/pt unknown
- 2018-02-27 AU AU2018229817A patent/AU2018229817B2/en active Active
- 2018-02-27 KR KR1020257014818A patent/KR20250065940A/ko active Pending
- 2018-02-27 HR HRP20250684TT patent/HRP20250684T1/hr unknown
- 2018-02-27 JP JP2019548560A patent/JP7157071B2/ja active Active
- 2018-02-27 LT LTEPPCT/FI2018/050143T patent/LT3592732T/lt unknown
- 2018-02-27 CA CA3055019A patent/CA3055019A1/en active Pending
- 2018-02-27 EP EP18709661.5A patent/EP3592732B1/en active Active
- 2018-02-27 KR KR1020197029193A patent/KR102676383B1/ko active Active
- 2018-02-27 RS RS20250547A patent/RS66855B1/sr unknown
- 2018-02-27 EA EA201992103A patent/EA201992103A1/ru unknown
- 2018-02-27 UA UAA201910164A patent/UA126071C2/uk unknown
- 2018-02-27 DK DK18709661.5T patent/DK3592732T3/da active
- 2018-02-27 CN CN201880016135.3A patent/CN110382467B/zh active Active
- 2018-02-27 KR KR1020247018685A patent/KR20240096691A/ko not_active Ceased
- 2018-02-27 NZ NZ797194A patent/NZ797194A/en unknown
- 2018-02-27 CN CN202511412369.8A patent/CN121021396A/zh active Pending
- 2018-02-27 MX MX2019010452A patent/MX2019010452A/es unknown
- 2018-02-27 PL PL18709661.5T patent/PL3592732T3/pl unknown
- 2018-02-27 ES ES18709661T patent/ES3027971T3/es active Active
- 2018-02-27 WO PCT/FI2018/050143 patent/WO2018162793A1/en not_active Ceased
- 2018-02-27 EP EP25162995.2A patent/EP4559527A3/en active Pending
- 2018-02-27 SI SI201831234T patent/SI3592732T1/sl unknown
- 2018-02-27 US US16/491,642 patent/US11168058B2/en active Active
- 2018-02-27 HU HUE18709661A patent/HUE071505T2/hu unknown
-
2019
- 2019-09-04 CL CL2019002540A patent/CL2019002540A1/es unknown
-
2023
- 2023-09-20 CL CL2023002780A patent/CL2023002780A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002540A1 (es) | Fabricación de un producto farmacéutico cristalino. | |
| CY1121062T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer | |
| MX2020010674A (es) | Agonistas del receptor muscarinico. | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| DOP2013000263A (es) | Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer | |
| MX2021015102A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| TW201613902A (en) | Difluoropyrrolidines as orexin receptor modulators | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| MX2022009155A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| PH12017500503A1 (en) | Mono- or di-substituted indoles as dengue viral replication inhibitors | |
| PH12016501724A1 (en) | Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| JOP20180071A1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| TW201613932A (en) | Organic compounds | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| PL3199171T3 (pl) | Kompozycja farmaceutyczna do leczenia i zapobiegania degeneracyjnym zaburzeniom neurologicznym, zawierająca, jako składnik aktywny, mieszaninę ekstraktu z kory korzenia piwonii drzewiastej, korzenia dzięgielu dahuryjskiego i korzenia przewiercienia lub ich frakcję | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| GEP20186908B (en) | P-substituted asymmetric ureas and medical uses thereof | |
| EP4219507A3 (en) | Thienopyrimidinone nmda receptor modulators and uses thereof | |
| PH12015502676A1 (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| PH12019501785A1 (en) | Intranasal composition comprising betahistine |